Ebola Contract Drives 70 Percent Rise in Tekmira's Q1 Revenues; Supports LNP Scale-up

Tekmira officials said that under the Ebola contract, the company has been able to scale up its lipid nanoparticle technology to support late clinical development and therapeutic manufacturing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.